# US 2004/0023984 A1 · Compounds for the treatment of alzheimer's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0023984 A1
- Document ID: US20040023984A1
- Status: Published application
- Kind: A1
- Application number: 10/397,682
- Filed: 2003-03-26
- Published: 2004-02-05
- Earliest claimed: 1987-01-15
- Assignees: Bonnie Davis
- Inventors: Bonnie M. Davis; Madeleine M. Joullie
- Web page: https://patentgrep.com/patent/US20040023984A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/665: having oxygen as a ring hetero atom, e.g. fosfomycin
- C07D 491/10: Spiro-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention is directed to analogs of galanthamine of the structure 1 and their use in treating Alzehimer's diseases and related dementias.

## Claims

### Claim 1

A method of treating Alzheimer's disease and related dementias which comprises administering to a patient suffering from such a disease a therapeutically effective amount of a compound of the Formula I
51
wherein the broken line represents an optionally present double bond in one or two of the positions shown, R1 and R2 are each selected independently from the group consisting of hydrogen, hydroxyl, amino, phenylamino or alkylamino, cyano, sulfhydryl, alkoxy of 1-6 carbon atoms, alkylthio, aryloxy, aralkoxy, C1-6 alkyl carbonate or R5-substituted phenyl or benzyl carbonate, R5-substituted aryloxy, R5-substituted arylthio, aralkoxy t an aliphatic or aryl carbamyl group wherein the aliphatic or aryl moiety may be R5 substituted or unsubstituted, aralkylthio, R5-substituted aryloxymethyl, alkanoyloxy, hydroxy-substituted alkanoyloxy, benzoyloxy, aryloxy carbonyl, R1 may also be alkyl of up to 14 carbon atoms, or hydroxy methyl, R2 may also be carboxymethyl provided that at least one of R1 and R2 is hydroxy, amino or alkylamino unless R7 or R8 is hydroxymethyl,
R3 is hydrogen, straight or branched chain alkyl of 1-6 carbon atoms, cycloalkyl methyl, phenyl, R5 substituted phenyl, alkylphenyl, R5 alkylphenyl, heterocyclic selected from α- or β-furyl, α- or β-thienyl or thenyl, pyridyl, pyrazinyl and pyrimidyl, alkyl heterocyclic or R′-substituted heterocyclyl, where R′ is alkyl or alkoxy and heterocyclyl is selected from α- or
β-furyl, thienyl, thenyl, pyridyl, pyrazinyl, pyrimidyl or is methylpyrryl or
R3 is alkanoyl of 1 to 8 carbon atoms or aroyl wherein the aryl group is of 6 to 10 carbon atoms, the alkyl and aryl portions of said groups optionally being substituted by R5 groups as hereinafter defined or
R3 is the residue of a compound having adrenergic or monoamino oxidase activity and said residue being selected from the group consisting of
52
wherein Hal is a halogen, p is 0, 1 or 2, q is 0 or 1, r is 0 or 1 and Z is selected from the group consisting of
53
wherein Q is hydrogen or hydroxy, L is hydrogen or C1-4 alkyl, G is hydrogen, C1-4 alkyl, alkylphenyl wherein said phenyl group is optionally substituted by hydroxy or methylene deoxy, or is alkylamino
54
wherein G is as defined above,
55
c) CH2CH2NH—NH2 and
56
each R4 is independently selected from hydrogen, hydroxyl, sulfhydryl, alkyl, aryl, alkoxy, mercaptoalkyl, aryloxy, mercaptoaryl, alkarloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, N-alkarylamino, fluoro, chloro, bromo iodo and trifluoromethyl, R5 is selected from the group consisting of hydroxyl, sulfhydryl, alkyl, aryl, alkoxy, mercaptoalkyl, aryloxy, mercaptoaryl, alkaryloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, fluoro, chloro, bromo, iodo and trifluoromethyl,
R6 is hydrogen, halo, trifluoromethyl or alkyl of 1 to 4 carbon atoms,
R7 is selected from the same groups as R4 or may be hydroxy alkyl of 1-2 carbon atoms,
R8 is hydrogen or hydroxymethyl,
R9 is hydrogen or alkyl of 1 to 6 carbon atoms, or when R2 is hydroxyl R9 may be
57
or
R2 and R9 may jointly form a keto group provided that R1 is hydroxy or amino,
X is oxygen or NH
Y is nitrogen
with the proviso that when X is O, R3 is not methyl when R1 is methoxy, R2 is hydroxy, all R4's are hydrogen or a pharmaceutically acceptable acid addition salt thereof.

### Claim 2 (depends on 1)

A method according to claim 1 wherein the compounds used is on wherein R1 and R2 are each selected from
H, OR, SH, NH2, NHR,
CH2OH, CONHR
58
wherein R is alkyl 1-6 carbon atoms or phenyl or naphthyl or R5-substituted naphthyl or R5-substituted phenyl or benzyl or R5-substituted benzyl, wherein R5 is as defined in claim 1 and R10 is hydrogen, alkyl or alkoxy, R3 is —H, or branched or linear alkyl or
—CH2—CH (CH2)n
wherein n is 3, 4 or 5,
59
wherein R11 is as defined for R10 above or is hydroxy or amino or R3 is
60
wherein Z is O, S, or NH or
61
X is oxygen and Y is nitrogen.

### Claim 3 (depends on 1)

A method according to claim 1 wherein said compound is of the formula
62
wherein R1 is hydroxy, lower alkoxy, aryloxy, R5 substituted aryloxy, benzyloxy or R5 substituted benzyloxy, amino, alkylamino or an alkyl or aryl carbamyl group.

### Claim 4 (depends on 3)

A method according to claim 3, wherein R1 is selected from the group consisting of hydroxy, methoxy, ethoxy, mono lower alkyl carbamate, phenyl carbamate, naphthyl carbamate, R5-substituted phenyl carbamate and R5-substituted naphthyl carbamate wherein R5 is hydroxyl, sulfhydryl, alkyl, aryl, alkoxy, mercaptoalkyl, aryloxy, mercaptoaryl, alkaryloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, N-alkarylamino, fluoro, chloro, bromo, iodo or trifluoromethyl.

### Claim 5 (depends on 3)

A method according to claim 3, wherein said compound is selected from N-desmethyl galanthamine, O-desmethyl, N-desmethyl galanthamine; 13-O-ethyl, O-desmethyl, N-desmethyl galanthamine; 13-O-phenyl, O-desmethyl, N-desmethyl galanthamine; and 13-O-benzyl, O-desmethyl, N-desmethyl galanthamine; O-desmethyl, N-desmethyl, N-ethyl galanthamin; O-desmethyl, N-desmethyl, N-ethyl galanthamine, 13-O-methyl, 13-O-ethyl and 13-O-benzyl ethers; O-desmethyl, N-desmethyl, N-ethyl galanthamine, 13-phenyl, 13-α-naphthyl, 13-dimethyl and 13-diethyl carbamates; O-desmethyl, N-desmethyl, N-cyclopropyl methyl galanthamine; O-desmethyl, N-desmethyl, N-cyclopropyl methyl galanthamine, 13-O-methyl, 13-O-ethyl and 13-O-benzyl ethers; O-desmethyl, N-desmethyl, N-cyclopropylmethyl galanthamine, 13-phenyl, 13-d-α-naphthyl, 13-dimethyl and 13-diethyl carbamates; O-desmethyl, N-desmethyl, N-benzyl galanthamine; O-desmethyl, N-desmethyl, N-benzyl galanthamine, 13-O-methyl, 13-O-ethyl and 13-O-benzyl ethers and O-desmethyl, N-desmethyl, N-benzyl galanthamine.

### Claim 6 (depends on 1)

A method according to claim 1 wherein said compound is of the formula:
63
wherein R2 is hydroxy, lower alkoxy, aryloxy, R5-substituted aryloxy, benzyloxy or R5-substituted benzyloxy or is an alkyl or aryl carbamyl group and R3 is hydrogen or alkyl of 1-6 carbon atoms, methyl cyclopropyl or benzyl or R5-substituted benzyl wherein R5 is hydroxyl, sulfhydryl, alkyl, aryl, alkoxy, mercaptoalkyl, aryloxy, mercaptoaryl, alkaryloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, N-alkarylamino, fluoro, chloro, bromo, iodo or trifluoromethyl.

### Claim 7 (depends on 6)

A method according to claim 6 wherein R2 is selected from the group consisting of hydroxy, methoxy, mono lower alkyl carbamate, phenyl carbamate, naphthyl carbamate, R5-substituted phenyl carbamate, R5-substituted naphthyl carbamate, lower alkanoyloxy benzoyloxy and R5-substituted benzoyloxy wherein R5 is hydroxyl, sulfhydryl, alkyl, aryl, -alkoxy, mercaptoalkyl, aryloxy, mercaptoaryl, alkaryl, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, N-alkarylamino, fluoro, chloro, bromo iodo or trifluoromethyl.

### Claim 8 (depends on 7)

A method according to claim 7 wherein R3 is selected from the group consisting of hydrogen, methyl and ethyl.

### Claim 9 (depends on 6)

A method according to claim 6, wherein said compound is selected from O-desmethyl galanthamine; O-demethyl galanthamine, O-methyl ether; O-desmethyl galanthamine, O-ethyl ether; O-desmethyl galanthamine, O-benzyl ether; O-desmethyl galanthamine, phenyl and O-desmethyl N-desmethyl galanthamine, α-naphthyl carbamates; O-desmethyl galanthamine dimethyl carbamate and O-desmethyl galanthamine diethyl carbamate wherein the carbamyl group is bonded to the oxygen of the cyclohexene ring, O-desmethyl N-desmethyl galanthamine; O-desmethyl N-desmethyl galanthamine, O-methyl, O-ethyl and O-benzyl ethers wherein etherification is at the 2-position; O-desmethyl N-desmethyl galanthamine phenyl, α-naphthyl, dimethyl and diethyl carbamates wherein the carbamate substitution is at the 2-position, O-desmethyl-N-desmethyl-N-ethyl galanthamine; O-desmethyl-N-desmethyl-N-ethyl galanthamine, O-methyl, O-ethyl or O-benzyl ether wherein said etherification is in the 2-position; O-desmethyl-N-desmethyl-N-ethyl galanthamine phenyl, α-naphthyl, dimethyl or diethyl carbamate wherein said carbamate substitution is in the 2-position; O-desmethyl-N-desmethyl-N-cyclopropyl methyl galanthamine, O-methyl, O-ethyl or O-benzyl ether wherein said etherification is in the 2-position; O-desmethyl-N-desmethyl-N-cyclopropylmethyl galanthamine, O-desmethyl-N-desmethyl-N-cyclopropylmethyl galanthamine, O-methyl, O-ethyl or O-benzyl ether wherein said etherification is in the 2-position; O-desmethyl-N-desmethyl-N-cyclopropylmethyl galanthamine phenyl, α-naphthyl, dimethyl or diethyl carbamate wherein said carbamate substitution is in the 2-position; O-desmethyl-N-desmethyl-N-benzyl galanthamine; O-desmethyl-N-desmethyl-N-benzyl galanthamine, O-methyl, O-ethyl or O-benzyl ether wherein said etherification is in the 2-position, O-desmethyl-N-desmethyl-N-benzyl galanthamine phenyl, α-naphthyl, dimethyl or diethyl carbamate wherein the carbamate substitution is in the 2-position.

### Claim 10 (depends on 1)

A method according to claim 1, wherein said compound is of the formula:
64
wherein R1, R2 and R3 are as defined in claim 1.

### Claim 11 (depends on 10)

A method according to claim 10, wherein the compound employed is one wherein R1 is hydroxy, lower alkoxy, benzyloxy or R5 substituted benzyloxy, amino alkylamino or alkyl or aryl carbamyl, R2 is hydroxy, lower alkoxy, aryloxy, benzyloxy or an alkyl or aryl carbamyl group and R3 is hydrogen, methyl, ethyl, cyclopropyl methyl or benzyl.

### Claim 12 (depends on 11)

A method according to claim 11, wherein said compound is selected from O-desmethyl lycoramine; N-desmethyl, O-desmethyl lycoramine; N-desmethyl N-ethyl lycoramine; N-desmethyl N-cyclopropylmethyl lycoramine; N-desmethyl N-benzyl lycoramine; O-desmethyl lycoramine ethyl ether; 2-deoxy-13-O-desmethyl lycoramine; 2-O-deoxy-13-O-desmethyl lycoramine, benzyl ether O-desmethyl lycoramine-dimethyl carbamate, O-desmethyl lycoramine phenyl carbamate, -2-O-deoxy-13-desmethyl lycoramine dimethyl carbamate and 2-O-deoxy-13-desmethyl lycoramine dimethyl carbamate.

### Claim 13 (depends on 1)

A method according to claim 1, wherein said compound is of the formula:
65
wherein R3 is selected from hydrogen, lower alkyl, cycloalkyl methyl or benzyl.

### Claim 14 (depends on 1)

A method according to claim 1 wherein said compound of formula I is one wherein R1 is hydroxy, methoxy, ethoxy, acetyloxy or carbamoyl of the formula CONHR11 wherein R11 is selected from the group consisting of methyl, ethyl, n-propyl, n-butyl, n-valeryl, phenyl, naphthyl, and fluoro- or nitro-substituted phenyl or naphthyl, R2 is hydroxy, methoxy, ethoxy, acetyloxy, propionyloxy, n-valeroyloxy, i-valeroyloxy or CONHR11 wherein R11 is as defined above and R3 is hydrogen, methyl or ethyl.

### Claim 15 (depends on 14)

A method according to claim 14, wherein in the compound employed, the ring to which R2 is bonded is a cyclohexane ring.

### Claim 16 (depends on 1)

A method according to claim 1 wherein the compound employed is selected from the group consisting of galanthamine n-butyl carbamate, galanthamine acetate, O-demethyl galanthamine-13-methylcarbamate, N-demethyl galanthamine and childanthine.

### Claim 17 (depends on 1)

A method according to claim 1, wherein the administration is parenteral at a daily dosage of 0.5-1,000 mg of a compound of formula 1 as specified in claim 1 or a pharmaceutically-acceptable acid addition salt thereof.

### Claim 18 (depends on 3)

A method according to claim 3, wherein the administration is parenteral at a daily dosage of 0.5-1,000 mg of a compound of as specified in claim 3 or a pharmaceutically-acceptable acid addition salt thereof.

### Claim 19 (depends on 10)

A method according to claim 10, wherein the administration is parenteral at a daily dosage of 0.5-1,000 mg of said compound.

### Claim 20 (depends on 13)

A method according to claim 13, wherein the administration is parenteral at a daily dosage of 0.5-1,000 mg of said compound.

### Claim 21 (depends on 1)

A method according to claim 1, wherein a compound of Formula I is administered at a dosage rate of 0.1-300 mg per day.

### Claim 22 (depends on 1)

A method according to claims 1, wherein said compound is administered orally at a dosage in the range 0.1-2000 mg per day.

### Claim 23 (depends on 3)

A method according to claim 3, wherein said compound is administered orally at a dosage in the range 0.1-2000 mg per day.

### Claim 24 (depends on 13)

A method according to claim 13, wherein said compound is administered orally at a dosage in the range 0.1-200 per day.

### Claim 25 (depends on 24)

A method according to claim 24, wherein said dosage rate of 0.1-200 mg per day.

### Claim 26 (depends on 1)

A method according to claim 1, wherein said compound is administered at a dosage rate of 0.001 to 4 mg/kg body weight of a patient, parenterally.

### Claim 27 (depends on 1)

A method according to claims 1, wherein a compound is administered intracerebroventricularly via an implanted reservoir at a dosage rate of 0.0001 to 5.0 mg/kg per day.

### Claim 28 (depends on 1)

A method according to any one of claim 1, wherein a compound is administered in a sustained release formulation.

### Claim 29

A compound of the formula
66
wherein the broken line represents an optionally present double bond in one of the two positions shown, R1 and R2 are each selected independently from the group consisting of hydrogen, hydroxyl, amino or alkylamino, cyano, sulfhydryl, alkoxy preferably of 1-6 carbon atoms, alkylthio, aryloxy, arylthio, R5-substituted aryloxy, R5-substituted arylthio, aralkoxy, an aliphatic or aryl carbamyl group wherein the aliphatic or aryl moiety may be R5 substituted or unsubstituted, aralkylthio, R5-substituted aralkoxy, R5-substituted aralkylthio, aryloxymethyl, R5 substituted aryloxymethyl, alkanoyloxy, hydroxy-substituted alkanoyloxy, benzoyloxy, R5-substituted benzoyloxy, aryloxy carbonyl and R5-substituted aryloxy carbonyl, R1 may also by alkyl of up to 14 carbon atoms, or hydroxy methyl, R2 may also be keto; R2 may also be carboxymethyl provided that at least one of R1 and R2 is hydroxy amino or alkylamino unless R7 or R8 is hydroxymethyl,
R3 is hydrogen, straight or branched chain alkyl, preferably of 1-6 carbon atoms, cycloalkyl methyl, alkylphenyl, R5-substituted alkylphenyl, heterocyclic selected from the group consisting of α- or β-furyl, α- or β-thienyl or thenyl, pyridyl, pyrazinyl or pyrimidyl groups or
R3 is an alkyl or alkoxy substituted derivative of said heterocyclic groups or
R3 is alkanoyl of 1 to 8 carbon atoms or aroyl wherein the aryl group is of 6 to 10 carbon atoms, the alkyl and aryl portions of said groups optionally being substituted by R5 groups as hereinafter defined or
R3 is the residue of a compound having adrenergic or monoamino oxidase activity and is selected from the group consisting of
67
wherein Hal is a halogen, preferably chloro, p is 0, 1 or 2, q is 0 or 1, r is 0 or 1 and Z is selected from the group consisting of
68
wherein Q is hydrogen or hydroxy, L is hydrogen or C1-4 alkyl, G is hydrogen, C1-4 alkyl, alkylphenyl wherein said phenyl group is optionally substituted by hydroxy or methylene deoxy, or is alkyl alkanylamino
69
wherein G is as defined above,
70
c) —CH2—CH2NH—NH2 and
71
each R4 is independently selected from hydrogen, hydroxyl, sulfhydryl, alkyl, aryl, aralkyl, alkoxy, mercaptoalkyl, aryloxy, mercaptoaryl, alkaryloxy, mercaptoalkylaryl, nitro, amino, N-alkylamino, N-arylamino, N-alkarylamino, fluoro, chloro, bromo, iodo, and trifluoromethyl, and R5 is selected from the groups consisting of hydroxyl, sulfhydryl, alkyl, aryl, alkoxy, mercaptoalkyl, aryloxy, mercaptoaryl, alkaryloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, N-alkarylamino, fluoro, chloro, bromo, iodo and trifluoromethyl,
R6 is hydrogen, halo, trifluoromethyl or alkyl of 1 to 4 carbon atoms,
R7 is selected from the same groups as R4 or may be hydroxy or mercapto alkyl of 1-2 carbon atoms,
R8 is hydrogen or hydroxymethyl,
R9 is hydrogen or alkyl of 1 to 6 carbon atoms, or when R2 is hydroxyl R9 may be
72
R2 and R9 may jointly form a semi carbazone, oxime, phenyl hydrazone or keto group,
and pharmaceutically-acceptable acid addition salts thereof with the provisoes that 1) is not methyl when R1 is methoxy, R2 is hydroxy, and all R4's are hydrogen, 2) that when the 3-4 bond is saturated that R1 is not hydrogen when R2 is methoxy or hydrogen, R4 is hydrogen, R3 is methyl and R7 is hydrogen or ethoxy, 3) R1 is not acetoxy when R2 is hydroxy, R3 is methyl, R4 is hydrogen and R7 is hydrogen, 4) when R2 is hydroxy, R3 is not hydrogen or benzyl when R1 is methoxy and all of R4 and R7 are hydrogen, and 5) that the compound is not leucotamine, O-methyl leucotamine, O-methyl leucotamine acetate, sanguinine, lycoramine, O-demethyl lycoramine, childanthine, habranthine, N-formyl galanthamine, acetyl dihydrogalanthamine or N,O-diacetyl N-demethyl galanthamine, deoxydemethyl lycoramine, dihydrochildanthine, sanguinine, dihydrosanguinine lycoramine acetate, deoxylycoramine or deoxydemethyl, lycoramine carbamate.

### Claim 30 (depends on 29)

A compound according to claim 29, wherein R1 is CONHR wherein R is alkyl of 1-6 carbon atoms, phenyl or R5-substituted phenyl or naphthyl or R5-substituted naphthyl or benzyl or R5 substituted benzyl wherein R5 is selected from hydroxy, sulfhydryl alkyl, aryl, aralkyl, alkoxy, thioalkyl, aryloxy, thioaryl, alkaryloxy, thioalkaryl, nitro, amino, N-alkylamino, N-arylamino, fluoro, chloro, bromo, iodo and trifluoromethyl; R2 is hydroxy, alkoxy of 1-6 carbon atoms, alkanoyloxy of 1-6 carbon atoms or CONHR wherein R is as defined above, R3 is hydrogen, lower alkyl or cyclopropyl substituted lower alkyl and R4, R6, R7, R8 and R9 are all hydrogen.

### Claim 31 (depends on 29, 32)

A compound according to claim 29 wherein R1 is hydroxy, alkoxy of 1-6 carbon atoms or alkanoyloxy of 1-6 carbon atoms, R2 is CONHR wherein R is as defined in claim 32, R3 is hydrogen, lower alkyl or cyclopropyl substituted lower alkyl and each of R4, R6, R7, R8 and R9 are hydrogen.

### Claim 32 (depends on 29)

A compound according to claim 29: galanthamine n-butyl carbamate.

### Claim 33 (depends on 29)

A compound according to claim 29: galanthamine n-propyl carbamate.

### Claim 34 (depends on 29)

A compound according to claim 29: galanthamine phenyl carbamate.

### Claim 35 (depends on 29)

A compound according to claim 29: galanthamine naphthyl carbamate.

### Claim 36 (depends on 29)

A compound according to claim 29: O-demethyl galanthamine-13-methyl carbamate.

### Claim 37 (depends on 29)

A compound according to claim 29: galanthamine acetate.

### Claim 38

A pharmaceutical composition for treatment of Alzheimer's disease and related dementias comprising a compound of the formula
73
wherein the broken line represents an optionally present double bond in one or two of the positions shown, R1 and R2 are each selected independently from the group consisting of hydrogen, hydroxyl, amino, phenylamino or alkylamino, cyano, sulfhydryl, alkoxy of 1-6 carbon atoms, alkylthio, aryloxy, aralkoxy, C1-6 alkyl carbonate or R5-substituted phenyl or benzyl carbonate, R5-substituted aryloxy, R5-substituted arylthio, aralkoxy, an aliphatic or aryl carbamyl group wherein the aliphatic or aryl moiety may be R5 substituted or unsubstituted, aralkylthio, R5-substituted aryloxymethyl, alkanoyloxy, hydroxy-substituted alkanoyloxy, benzoyloxy, aryloxy carbonyl, R1 may also be alkyl of up to 14 carbon atoms, or hydroxy methyl, R2 may also be carboxymethyl provided that at least one of R1 and R2 is hydroxy, amino or alkylamino unless R7 or R8 is hydroxymethyl,
R3 is hydrogen, straight or branched chain alkyl of 1-6 carbon atoms, cycloalkyl methyl, phenyl, R5 substituted phenyl, alkylphenyl, R5 alkylphenyl, heterocyclic selected from α- or β-furyl, α- or β-thienyl or thenyl, pyridyl, pyrazinyl and pyrimidyl, alkyl heterocyclic or R′-substituted heterocyclyl, where R′ is alkyl or alkoxy and heterocyclyl is selected from α- or
β-furyl, thienyl, thenyl, pyridyl, pyrazinyl, pyrimidyl or is methylpyrryl or
R3 is alkanoyl of 1 to 8 carbon atoms or aroyl wherein the aryl group is of 6 to 10 carbon atoms, the alkyl and aryl portions of said groups optionally being substituted by R5 groups as hereinafter defined or
R3 is the residue of a compound having adrenergic or monoamino oxidase activity and said residue being selected from the group consisting of
74
wherein Hal is a halogen, p is 0, 1 or 2, q is 0 or 1, r is 0 or 1 and Z is selected from the group consisting of
75
wherein Q is hydrogen or hydroxy, L is hydrogen or C1-4 alkyl, G is hydrogen, C1-4 alkyl, alkylphenyl wherein said phenyl group is optionally substituted by hydroxy or methylene deoxy, or is alkylamino
76
wherein G is as defined above,
77
c) CH2CH2NH—NH2 and
78
each R4 is independently selected from hydrogen, hydroxyl, sulfhydryl, alkyl, aryl, alkoxy, mercaptoalkyl, aryloxy, mercaptoaryl, alkarloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, N-alkarylamino, fluoro, chloro, bromo iodo and trifluoromethyl, R5 is selected from the group consisting of hydroxyl, sulfhydryl, alkyl, aryl, alkoxy, mercaptoalkyl, aryloxy, mercaptoaryl, alkaryloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, fluoro, chloro, bromo, iodo and trifluoromethyl,
R6 is hydrogen, halo, trifluoromethyl or alkyl of 1 to 4 carbon atoms,
R7 is selected from the same groups as R4 or may be hydroxy alkyl of 1-2 carbon atoms,
R8 is hydrogen or hydroxymethyl,
R9 is hydrogen or alkyl of 1 to 6 carbon atoms, or when R2 is hydroxyl R9 may be
79
or
R2 and R9 may jointly form a keto group provided that R1 is hydroxy or amino,
X is oxygen or NH
Y is nitrogen
with the proviso that when X is O, R3 is not methyl when R1 is methoxy, R2 is hydroxy, all R4's are hydrogen and a pharmaceutically acceptable solvent diluent or carrier.

### Claim 39 (depends on 38)

A composition according to claim 38 in the form of a Sustained release product.

### Claim 40

A method of treating Alzheimer's disease and related dementias comprising administering to a patient suffering from such a disease a therapeutically effective amount of lycoramine.
